Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJames B. Yu, MD, MHS, FASTRO
he/him/his
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
James Yu, MD, MHS, is Professor of Radiation Oncology and Genitourinary Cancers Radiotherapy Lead at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire.
He is a former Professor of Radiation Oncology at the Yale School of Medicine, former Associate Chief Medical Officer of the Smilow Cancer Hospital and Care Centers and Executive Vice Chair of Columbia University Irving Medical Center Department of Radiation Oncology.
In his academic work, Dr. Yu conducts research on ways to use radiotherapy treatments to improve outcomes for cancer patients. “We need to push the field ever forward and not be satisfied with merely prolonging survival,” says Dr. Yu. “I think radiosurgery will play a role in this. As systemic therapies improve and our ability to control microscopically disseminated disease improves, noninvasive ablative therapies will become ever more important.”
As a former Yale Center for Clinical Investigation scholar and founding member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, Dr. Yu’s research centers on the comparative effectiveness of new radiation technologies and how these new technologies are adopted nationally.
Dr. Yu is the Editor-in Chief of JNCI Cancer Spectrum, Deputy Editor-In-Chief of the journal Practical Radiation Oncology and is on the editorial boards of the Journal of Clinical Oncology - Clinical Cancer Informatics, JNCI, Journal of Surgical Oncology, and Oncology (Williston Park), and former editorial board member of the Journal of Clinical Oncology.
He has published over 350 original manuscripts and co-edited the textbook Pocket Radiation Oncology and Principles of Clinical Cancer Research. He is the radiation oncology co-chair for the Southwest Oncology Group Genitourinary Cancers Committee, and a nationally recognized expert in patient reported outcomes.
Last Updated on March 10, 2025.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- All Institutions
- Brain Tumor Center
- COPPER Center
- Gamma Knife Center
- Internal Medicine
- Medical Oncology and Hematology
- Pituitary Program
- Prostate & Urologic Cancers Program
- Radiation Oncology
- Yale Cancer Center
- Yale Ventures
- Yale-BI Biomedical Data Science Fellowship
Education & Training
- MHS
- Yale University, Masters of Health Science (2014)
- Resident
- Yale New Haven Hospital (2009)
- Chief Resident
- Yale School of Medicine (2009)
- Intern
- California Pacific Medical Center, San Francisco, CA (2005)
- MD
- University of Michigan Medical School (2004)
- BS
- Yale University (1999)
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Central Nervous System Neoplasms; Head and Neck Neoplasms; Radiotherapy, Intensity-Modulated; Urogenital Neoplasms
ORCID
0000-0002-3119-3226
Research at a Glance
Yale Co-Authors
Frequent collaborators of James B. Yu's published research.
Publications Timeline
A big-picture view of James B. Yu's research output by year.
Research Interests
Research topics James B. Yu is interested in exploring.
Henry S. Park, MD, MPH
Cary P Gross, MD
Veronica Chiang, MD, FAANS
Sanjay Aneja, MD
Kenneth B. Roberts, MD
Lynn D. Wilson, MD, MPH, FASTRO
452Publications
4,665Citations
Breast Neoplasms
Radiotherapy, Intensity-Modulated
Head and Neck Neoplasms
Publications
2026
Early-Stage Lung Cancer Treatment Disparities by Race Among Medicare Beneficiaries
Lynch O, Lee D, Soulos P, Yu J, Herrin J, Gross C. Early-Stage Lung Cancer Treatment Disparities by Race Among Medicare Beneficiaries. JAMA Network Open 2026, 9: e2559845. PMID: 41770564, PMCID: PMC12954539, DOI: 10.1001/jamanetworkopen.2025.59845.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMedicare beneficiariesRacial disparitiesStereotactic body radiotherapyWhite patientsBlack patientsNon-Hispanic white patientsEarly-stage NSCLCCancer treatment disparitiesLung cancer careCurative treatmentSEER-Medicare dataReceipt of surgeryCancer careSurgical treatmentDiagnosis of stage IRetrospective cohort studyMain OutcomesTreatment disparitiesSEER-MedicareCohort studyMedicareRacial differencesDisparitiesEnd ResultsAdjusted probabilityA randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL).
Posadas E, Gay H, Pugh S, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Howell K, Jurgens D, Wong A, Shen X, Miyawaki L, Thompson B, Braun S, Johnson T, Feng F, Nguyen P. A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2026, 44: 156-156. DOI: 10.1200/jco.2026.44.7_suppl.156.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyProgression free survivalStandard androgen deprivation therapySalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsLHRH analogsRadical prostatectomyAndrogen receptorImprovement of progression free survivalRate of biochemical failureRandomized phase 2 studyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyPhase 2 studyPost-RP patientsFollow-up timePhase 3 trialGleason 9Salvage radiationBiochemical failureAR blockadeDeprivation therapyTrends in high grade prostate cancer at diagnosis in the United States from 2004-2022.
Krishnan A, Feyisa J, Kapadia N, Yu J. Trends in high grade prostate cancer at diagnosis in the United States from 2004-2022. Journal Of Clinical Oncology 2026, 44: 341-341. DOI: 10.1200/jco.2026.44.7_suppl.341.Peer-Reviewed Original ResearchConceptsHigh-grade diseaseHigh grade diseaseNational Cancer DatabaseHigh-grade diagnosisProstate cancerGrade diseaseAcademic centersAssociated with higher likelihoodProportion of high-grade diseaseBiology of prostate cancerHigh grade prostate cancerHigh-grade prostate cancerAmerican CollegeNational Cancer Data BaseCancer-specific survivalHigh-grade casesGrade prostate cancerProstate cancer incidenceUnadjusted proportionProstate cancer gradeUnivariate logistic regressionAssociated with higher oddsNon-academic centersAmerican Cancer SocietyIndolent casesTrends in PSA and metastatic prostate cancer at presentation in the United States from 2004-2022.
Feyisa J, Krishnan A, Kapadia N, Yu J. Trends in PSA and metastatic prostate cancer at presentation in the United States from 2004-2022. Journal Of Clinical Oncology 2026, 44: 76-76. DOI: 10.1200/jco.2026.44.7_suppl.76.Peer-Reviewed Original ResearchConceptsMedian prostate-specific antigenProstate-specific antigenNational Cancer Data BaseMetastatic diseaseMetastatic stageProstate cancerPercentage of menIntroduction of prostate-specific antigenAverage prostate-specific antigenMetastatic stage of diseaseProstate-specific antigen levelDetection of metastatic diseaseIncidence of metastatic diseaseDiagnosis of prostate cancerMedian PSA levelPSMA PET-CTMetastatic prostate cancerProportion of patientsYear of diagnosisSensitive imaging modalityStage of diseasePSA levelsProstatic adenocarcinomaPET-CTAggressive diseaseSWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).
Ballas L, Callis S, Daneshmand S, Tripathi A, Hamstra D, Yu J, Tyson M, Mouw K, Meeks J, McConkey D, Rose K, Tawagi K, Mittal K, Sachdev S, Flaig T, Lerner S. SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT). Journal Of Clinical Oncology 2026, 44: tps913-tps913. DOI: 10.1200/jco.2026.44.7_suppl.tps913.Peer-Reviewed Original ResearchConceptsClinical complete responsePathological complete responseSingle arm phase II studyResponse to NATYears of pembrolizumabNeoadjuvant therapyMetastasis-free survivalRadical cystectomyBladder preservationComplete responseLocal therapyOverall survivalClinical complete response ratePathologic complete response rateResponse to neoadjuvant therapyMuscle invasive bladder cancerActive systemic therapyBladder preservation rateBladder preservation therapyFractions of radiotherapyEvent-free survivalRecurrence-free survivalInvasive bladder cancerLocal disease recurrencePhase 2 trialIntegrating Locoregional Therapies into Oncology Value Frameworks to Improve Patient-Centered Decision Making and Outcomes
Asare K, Corn B, Ennis R, Sapir E, Kapadia N, Gross C, Yu J. Integrating Locoregional Therapies into Oncology Value Frameworks to Improve Patient-Centered Decision Making and Outcomes. Practical Radiation Oncology 2026 PMID: 41771435, DOI: 10.1016/j.prro.2026.02.009.Peer-Reviewed Original ResearchAltmetricConceptsLocoregional therapyTreatment modalitiesLocal tumor controlLocal treatment modalitiesOrgan function outcomesPatient-centered decision makingLocoregional interventionsTumor controlSystemic therapyDrug treatmentFunctional outcomesOrgan preservationTherapeutic benefitTherapyHospitalization ratesOncologyModalitiesTreatmentOutcomesLocoregionallyFORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. European Urology 2026 PMID: 41672869, DOI: 10.1016/j.eururo.2025.12.001.Peer-Reviewed Original ResearchAltmetricConceptsPSA progression-free survivalMetastasis-free survivalProstate-specific antigenSalvage radiotherapyMulticenter randomized trialGnRH agonistAbiraterone acetate plus prednisoneMetastasis-free survival ratesAcetate plus prednisoneProgression-free survivalMedian Follow-UpHigh-risk featuresStandard treatment optionDetectable prostate-specific antigenRadical prostatectomyAbiraterone acetatePN statusPrimary endpointSecondary endpointsSafety profileAdverse eventsTreatment optionsFollow-upApalutamidePreplanned analysisIncidence of breast implant–associated anaplastic large cell lymphoma
Lowe L, Kim D, Rohde C, Yu J, Cheng S, Kachnic L, Horowitz D, Neugut A, Kinslow C. Incidence of breast implant–associated anaplastic large cell lymphoma. Journal Of The National Cancer Institute 2026, djag019. PMID: 41570109, DOI: 10.1093/jnci/djag019.Peer-Reviewed Original ResearchConceptsBreast implant-associated ALCLAnaplastic large cell lymphomaAge-adjusted incidence ratesBreast implant-associated anaplastic large cell lymphomaImplant-associated anaplastic large cell lymphomaU.S. standard populationSurveillance, EpidemiologyAge-adjusted incidenceEnd Results ProgramLarge cell lymphomaFood and Drug AdministrationStandard populationResults ProgramCell lymphomaDiagnostic codesProvisional entityWorld Health OrganizationBreast implantsDrug AdministrationAdult womenHealth OrganizationBreastLymphomaEpidemiologyWomenLow-Dose Radiotherapy for Osteoarthritis: Current Evidence, Practical Recommendations and Future Perspectives
Schlamann A, Yu J, Rühle A. Low-Dose Radiotherapy for Osteoarthritis: Current Evidence, Practical Recommendations and Future Perspectives. Seminars In Radiation Oncology 2026, 36: 39-47. PMID: 41391897, DOI: 10.1016/j.semradonc.2025.07.001.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsLow-dose radiotherapyPatient selectionRisk of radiation-induced malignancyAbsolute riskShort follow-up durationStandard dosing regimensPlacebo-controlled studyRadiation-induced malignancyFollow-up durationNoninvasive therapeutic optionProportion of patientsSuboptimal patient selectionFavorable safety profileAnti-inflammatory effectsRandomized Controlled TrialsDose planningDosing regimensLow-doseRetrospective studySafety profileTherapeutic optionsPharmacological therapyClinical evidenceOptimal doseRandomized trials
2025
Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis
Folkert M, Weg E, Sato R, Yu J, Bhattacharyya S, Ezekekwu E, Hamstra D. Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis. Brachytherapy 2025, 25: 402-409. PMID: 41392003, DOI: 10.1016/j.brachy.2025.10.015.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsSpacer useProstate cancerBaseline dysfunctionSexual dysfunctionRectal spaceAssociated with significantly lower incidenceBeam radiation therapyMedian Follow-UpSignificant lower incidenceCox proportional hazards modelsProstate cancer brachytherapyReal-world studyProportional hazards modelBT modalitiesBT monotherapyLDR patientsLDR-BTRectal spacerMonotherapy patientsRadiation therapyCancer brachytherapyClaims data analysisSecondary cancersUrinary dysfunctionRetrospective study
Academic Achievements & Community Involvement
Copy Link
Honors
honor Fellow
07/17/2023National AwardAmerican Society for Radiation OncologyDetailsUnited Stateshonor Cancer Prevention and Control Research Prize
12/31/2017Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Population Research Prize
11/22/2013Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Seattle Prostate Brachytherapy Fellow
01/01/2009National AwardAmerican Brachytherapy SocietyDetailsUnited Stateshonor Young Oncologist Essay Award
01/01/2008National AwardAmerican Radium SocietyDetailsUnited States
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email